Next Post

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

[ad_1] Enrollment proceeds in Period 1 dose-escalation IMMUNICY-1 demo for direct shRNA-based mostly allogeneic Motor vehicle T candidate, CYAD-211, for relapsed/refractory various myeloma (r/r MM) Dialogue carries on with regulatory businesses relating to CYAD-101-002 Period 1b trial, which remains on medical hold MONT-SAINT-GUIBERT, Belgium, Could 05, 2022–(Business WIRE)–Regulatory Information: This […]

Subscribe US Now